Investments
29Portfolio Exits
12About Ridgeback Capital Management
Ridgeback Capital is a healthcare hedge fund founded by Wayne Holman in 2006. Wayne Holman previously worked at Steve Cohen's subsidiary Sigma Capital. The fund has more than $500 million in AUM.
Want to inform investors similar to Ridgeback Capital Management about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Ridgeback Capital Management News
Dec 7, 2021
This brings the company's total financing to over $800 million since the company was founded in 2014. This round of financing was led by investors Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc. In addition, there were several new biotech institutional investors well-placed to support the company's mission including ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, and other undisclosed funds. Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Ridgeback Capital Management Investments
29 Investments
Ridgeback Capital Management has made 29 investments. Their latest investment was in Quell Therapeutics as part of their Series B on November 11, 2021.
Ridgeback Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/29/2021 | Series B | Quell Therapeutics | $156M | Yes | 18 | |
11/9/2021 | Series B | Arbor Biotechnologies | $215M | Yes | Ally Bridge Group, ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Sandler, Ridgeback Capital Management, Section 32, Surveyor Capital, T. Rowe Price, Tao Capital Partners, TCG Crossover, Tekla Capital Management, Temasek, Vertex Pharmaceuticals, and Woodline Partners | 13 |
9/23/2021 | Series A | Garuda Therapeutics | $72M | Yes | 17 | |
7/14/2021 | Series D | |||||
5/6/2021 | Series B |
Date | 11/29/2021 | 11/9/2021 | 9/23/2021 | 7/14/2021 | 5/6/2021 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series A | Series D | Series B |
Company | Quell Therapeutics | Arbor Biotechnologies | Garuda Therapeutics | ||
Amount | $156M | $215M | $72M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Ally Bridge Group, ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Sandler, Ridgeback Capital Management, Section 32, Surveyor Capital, T. Rowe Price, Tao Capital Partners, TCG Crossover, Tekla Capital Management, Temasek, Vertex Pharmaceuticals, and Woodline Partners | ||||
Sources | 18 | 13 | 17 |
Ridgeback Capital Management Portfolio Exits
12 Portfolio Exits
Ridgeback Capital Management has 12 portfolio exits. Their latest portfolio exit was Turnstone Biologics on July 21, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/21/2023 | IPO | Public | 2 | ||
12/20/2021 | Acq - Pending | 3 | |||
10/8/2021 | IPO | Public | 9 | ||
Date | 7/21/2023 | 12/20/2021 | 10/8/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acq - Pending | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 2 | 3 | 9 |
Ridgeback Capital Management Team
2 Team Members
Ridgeback Capital Management has 2 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Wayne Holman | Founder | Current | |
Name | Wayne Holman | |
|---|---|---|
Work History | ||
Title | Founder | |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
